Initiative Includes Milestone-Based Inventory Purchase Commitments During Q1 and Q2, 2025Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX)...
Inretio presents initial clinical trial results at prestigious BRAIN Conference 2024 in London.Toronto, Ontario--(Newsfile Corp. - December 11, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE:...
Distributors' medical partner networks impressed with Venowave device, speed of Medicare/Medicaid processing and prepare roadmaps to drive salesToronto, Ontario--(Newsfile Corp. - December 5, 2024) - Therma...
Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment partner in advanced diagnostic and medical device technologies,...
InStatin to secure exclusive worldwide licensing agreement of InVixa's inhaled statin solution to prevent and treat acute lung diseaseToronto, Ontario--(Newsfile Corp. - October 28, 2024) - Therma Bright...
Clinical research will offer insight for specific targeting of active pharmaceutical ingredients (API) that will further support Phase 1 Human Trials.Toronto, Ontario--(Newsfile Corp. - September 23, 2024)...
New Advisory Board Member will focus on Venowave sales and business development effortsToronto, Ontario--(Newsfile Corp. - September 12, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma"...
Therma Bright's Venowave VW5, a circulation-boosting device, has secured a crucial Medicare & Medicaid designation, opening up a massive market opportunity for the company.
Chairman of Therma Bright's Strategic Investment Partner Recognized for Outstanding Research and Discovery in Respiratory Drug DeliveryToronto, Ontario--(Newsfile Corp. - September 4, 2024) - Therma Bright...
Game-Changing Innovation Poised to Transform Stroke and Blood Clot TreatmentTherma Bright's Strategic Investment Helps Medical Device Company Demonstrate Efficacy and Safety in Transforming Ischemic Stroke...